Disclaimer: This information is intended for educational purposes only and should not be considered medical advice. It is designed to supplement, not replace, the knowledge, skill, and judgment of healthcare professionals. Patient care decisions must always be made in the context of individual patient circumstances, clinical judgment, and current medical evidence. Always consult with a qualified healthcare provider for diagnosis and treatment of any medical condition.

---

Shingles

Overview

• Definition: Shingles, also known as herpes zoster (HZ), is a painful viral rash caused by the reactivation of the varicella-zoster virus (VZV), the same virus that causes chickenpox. After an initial chickenpox infection, VZV remains latent in sensory nerve ganglia and can reactivate later in life, typically due to a decline in cell-mediated immunity, leading to the characteristic dermatomal rash and associated pain.
• Epidemiology:
  • Incidence: Approximately 1 million cases occur annually in the United States. Lifetime risk of developing shingles is about 30%.
  • Age: Incidence increases sharply with age, particularly after 50 years. Over half of all cases occur in individuals aged 60 years or older.
  • Demographics: Affects all races and genders equally.
  • Immunocompromise: Incidence is significantly higher and disease course is often more severe in immunocompromised individuals (e.g., HIV/AIDS, cancer, organ transplant recipients, those on immunosuppressive medications).
  • Recurrence: Recurrence is possible, though less common, affecting 1-6% of individuals.
• Classification:
  • Dermatomal Shingles: The most common form, characterized by a unilateral rash limited to one or more contiguous dermatomes.
  • Zoster Ophthalmicus (Herpes Zoster Ophthalmicus, HZO): Shingles involving the ophthalmic division (V1) of the trigeminal nerve. Potentially sight-threatening. Often indicated by vesicles on the tip of the nose (Hutchinson's sign), which correlates with nasociliary nerve involvement.
  • Zoster Oticus (Ramsay Hunt Syndrome): Shingles involving the geniculate ganglion, affecting cranial nerves VII (facial) and often VIII (vestibulocochlear). Characterized by facial paralysis, ear pain, and vesicles in the external auditory canal or on the auricle. Can also cause tinnitus, vertigo, and hearing loss.
  • Disseminated Zoster: Rare, but serious form where the rash extends beyond the primary dermatome to involve ≥2 noncontiguous dermatomes, or involves internal organs (e.g., lungs, CNS, liver). Typically occurs in severely immunocompromised individuals.
  • Zoster Sine Herpete (Zoster without rash): Characterized by dermatomal pain without the typical rash. Diagnosis is challenging and requires laboratory confirmation (e.g., VZV DNA PCR from CSF in cases of suspected CNS involvement).

Pathophysiology

• Mechanism:
  1. Primary Infection: Initial infection with VZV causes chickenpox, typically during childhood.
  2. Latency: After primary infection, VZV is not eradicated but becomes latent, persisting indefinitely within the sensory ganglia (e.g., dorsal root ganglia, trigeminal ganglia, cranial nerve ganglia) along the entire neuraxis.
  3. Reactivation Triggers: A decline in VZV-specific cell-mediated immunity (CMI) is the primary trigger for reactivation. This decline can occur due to:
     • Aging: Natural waning of CMI with increasing age.
     • Immunosuppression: Diseases (e.g., HIV/AIDS, malignancies like lymphoma/leukemia) or medications (e.g., corticosteroids, chemotherapy, immunosuppressants for organ transplant or autoimmune diseases) that suppress the immune system.
     • Stress/Trauma: Physical or emotional stress, local trauma, or surgery in the affected dermatome may precipitate reactivation, though this link is less clear.
  4. Viral Replication and Spread: Upon reactivation, VZV replicates within the sensory ganglion, causing inflammation and neuronal damage. The virus then travels anterograde along the sensory nerve fibers to the skin, where it replicates in keratinocytes, leading to the characteristic vesicular rash.
  5. Pain Generation: Viral replication and inflammation in the ganglion and nerve lead to neuronal damage, deafferentation, and central sensitization, contributing to the severe neuropathic pain characteristic of shingles and, in some cases, post-herpetic neuralgia (PHN).
• Risk Factors:
  • Age: The strongest risk factor; incidence rises sharply after age 50.
  • Immunocompromised States:
    • HIV/AIDS (CD4 count <200 cells/µL).
    • Malignancies (especially lymphoma, leukemia).
    • Solid organ or hematopoietic stem cell transplant recipients.
    • Autoimmune diseases (e.g., rheumatoid arthritis, lupus) and their treatments (e.g., high-dose corticosteroids, biologic agents like TNF-alpha inhibitors).
    • Chemotherapy or radiation therapy.
  • Recent Trauma or Surgery: To a dermatome, though less consistently linked.
  • Stress: Severe emotional or physical stress.
  • Fetal Exposure to VZV: In utero exposure to VZV can lead to a higher risk of HZ during childhood or adolescence.
• Protective Factors:
  • Vaccination: The most effective protective factor against shingles and its complications, particularly post-herpetic neuralgia.
    • Recombinant Zoster Vaccine (RZV, Shingrix): Highly effective, recommended for most adults ≥50 years old.
  • Robust Cell-Mediated Immunity: A healthy immune system capable of controlling latent VZV.
  • Prior Episodes of Chickenpox (Wild-Type): While prior chickenpox is a prerequisite for shingles, robust CMI developed from it helps keep the virus latent. However, CMI wanes over time, allowing reactivation.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Pain: Often the first symptom, occurring days (typically 1-4 days) before the rash appears (prodrome). Described as burning, stabbing, aching, throbbing, or shooting. Usually localized to a dermatomal distribution. Can be severe.
  • Rash: A characteristic vesicular eruption on an erythematous base, confined to a single dermatome (unilateral) or occasionally contiguous dermatomes.
    • Initially, macules and papules evolve into vesicles (fluid-filled blisters) over 12-24 hours.
    • Vesicles become pustular, then crust over, typically healing in 2-4 weeks.
    • New lesions may continue to appear for 3-5 days.
• Early Signs (Prodromal Phase):
  • Unilateral localized pain, itching, tingling, or paresthesias in the affected dermatome.
  • Malaise, headache, low-grade fever, or fatigue may precede the rash by several days.
  • Hyperesthesia or allodynia (pain from normally non-painful stimuli) in the affected area.
• Advanced Signs (Eruptive Phase and Resolution):
  • Full development of the characteristic vesicular rash.
  • Increasing pain severity as vesicles develop.
  • Vesicles rupture, weep, and form crusts.
  • Crusts eventually fall off, often leaving behind hyperpigmentation or hypopigmentation, and sometimes scarring, especially if secondary bacterial infection occurred.
  • Pain may persist for weeks to months after rash resolution (post-herpetic neuralgia).
• Atypical Presentations:
  • Disseminated Zoster: Rash lesions extending beyond the primary dermatome to involve ≥2 noncontiguous dermatomes or internal organs. Seen mostly in severely immunocompromised patients.
  • Zoster Ophthalmicus (HZO): Rash involving the forehead, scalp, and nose tip (Hutchinson's sign, indicating nasociliary nerve involvement and increased risk of ocular complications). Pain around the eye, eye redness, photophobia.
  • Zoster Oticus (Ramsay Hunt Syndrome): Facial paralysis (often unilateral), ear pain, vesicles on the auricle or external auditory canal, taste disturbance, vertigo, tinnitus, or hearing loss.
  • Zoster Sine Herpete: Dermatomal pain without a rash. Difficult to diagnose clinically, usually requires laboratory confirmation (e.g., VZV PCR from CSF if neurological symptoms are present).
  • Motor Zoster: Rarely, motor weakness can occur in the affected dermatome due to viral spread to anterior horn cells.

Physical Examination

• Inspection:
  • Rash Morphology: Observe erythematous macules and papules progressing to grouped vesicles on an erythematous base, often unilateral and strictly confined to one or more contiguous dermatomes. Vesicles may be clear, cloudy, or hemorrhagic.
  • Distribution: Note the dermatomal pattern (e.g., thoracic T3-T5 most common, followed by trigeminal nerve distribution).
  • Stage of Lesions: Presence of fresh vesicles, pustules, or crusts.
  • Hutchinson's Sign: Vesicles on the tip of the nose (for ophthalmic zoster), indicating nasociliary nerve involvement and high risk of ocular disease.
  • Scarring/Pigmentation: After healing, post-inflammatory hyperpigmentation or hypopigmentation, and potentially scarring.
  • Secondary Infection: Look for signs of bacterial superinfection (e.g., erythema, purulence, cellulitis).
• Palpation:
  • Tenderness: Palpation of the affected dermatome often elicits pain or hyperesthesia.
  • Lymphadenopathy: Regional lymphadenopathy (swollen, tender lymph nodes) may be present.
• Special Tests:
  • Ocular Exam (for HZO): Urgent ophthalmological consultation is crucial. Slit-lamp examination to assess for conjunctivitis, keratitis (dendritic ulcers), uveitis, scleritis, or acute retinal necrosis.
  • Cranial Nerve Exam (for Ramsay Hunt Syndrome): Assess for facial nerve palsy (e.g., inability to raise eyebrow, close eye, smile, puff cheeks), and audiometry or vestibular testing if hearing or balance issues are present.

Diagnostic Approach

History Taking

• Key Questions:
  • Prodromal Symptoms: Did pain, itching, or tingling precede the rash? Describe the character and location of the pain.
  • Rash Onset and Evolution: When did the rash appear? What did it look like initially? How has it changed over time (macules to vesicles to crusts)? Is it unilateral? Is it confined to a specific body area?
  • Pain Severity: Rate the pain (0-10), and describe its quality (burning, sharp, aching, shooting). Is it constant or intermittent?
  • Associated Symptoms: Fever, headache, malaise? Visual changes (pain, redness, blurred vision, photophobia)? Facial weakness or paralysis? Ear pain, hearing loss, vertigo, tinnitus?
  • Immunocompromised Status: History of HIV/AIDS, cancer, organ transplant? Use of immunosuppressive medications (e.g., corticosteroids, biologics, chemotherapy)?
  • Past Medical History: History of chickenpox? Prior episode of shingles?
  • Vaccination Status: Has the patient received the shingles vaccine (RZV)? If so, when and how many doses?
• Red Flags:
  • Ocular Involvement: Rash involving the forehead/nose (Hutchinson's sign), eye pain, redness, vision changes (blurry vision, photophobia). Requires urgent ophthalmology consultation.
  • Facial Weakness/Ear Symptoms: Rash on ear, ear pain, facial droop, hearing loss, vertigo. Suggests Ramsay Hunt syndrome. Requires urgent ENT consultation.
  • Disseminated Rash: Rash spreading widely across the body (beyond contiguous dermatomes) or appearing in immunocompromised patients. Indicates potential visceral involvement and requires hospitalization and IV antivirals.
  • Severe Pain or Neurological Deficits: Unrelenting pain despite analgesia, or new motor weakness, bowel/bladder dysfunction, altered mental status, or meningeal signs. May indicate myelitis, encephalitis, or other severe neurological complications.

Laboratory Tests

• First-Line:
  • Clinical Diagnosis: For most immunocompetent patients, shingles is a clinical diagnosis based on the characteristic dermatomal rash and pain. Laboratory confirmation is often not necessary to initiate treatment, especially when presentation is typical.
• Confirmatory (When atypical presentation, immunocompromised, or for research/epidemiology):
  • Polymerase Chain Reaction (PCR) for VZV DNA:
    • Specimen: Vesicular fluid, crusts, CSF (if CNS involvement suspected), or biopsy tissue.
    • Utility: Highly sensitive and specific. It is the preferred method for confirming VZV infection, especially in atypical presentations (e.g., zoster sine herpete, disseminated zoster) or when differentiation from herpes simplex virus (HSV) is necessary.
  • Direct Fluorescent Antibody (DFA) Staining:
    • Specimen: Scraped cells from the base of a fresh vesicle.
    • Utility: Can differentiate VZV from HSV. Provides rapid results but is less sensitive than PCR.
  • Tzanck Smear:
    • Specimen: Fluid from the base of a vesicle.
    • Utility: Detects multinucleated giant cells and intranuclear inclusions characteristic of herpes viruses (VZV, HSV), but cannot differentiate between them. Rarely used in modern practice due to low sensitivity and specificity compared to PCR/DFA.
  • Serology (IgM/IgG):
    • Utility: VZV IgM antibodies indicate recent or reactivated infection, but are not always reliable for diagnosis of acute HZ. IgG antibodies indicate past exposure but not acute infection. Serology is rarely used for acute diagnosis but can be helpful for determining immune status to VZV.
• Monitoring:
  • No routine lab monitoring for uncomplicated shingles.
  • For disseminated zoster or severe immunocompromise, monitor CBC, liver function tests, and renal function, especially if on IV antivirals.
  • If CNS complications are suspected, CSF analysis (VZV PCR) is essential.

Imaging

• Recommended:
  • Rarely indicated for uncomplicated shingles. Diagnosis is typically clinical.
• Advanced (When needed for complications):
  • Magnetic Resonance Imaging (MRI):
    • Utility: Indicated for suspected neurological complications (e.g., myelitis, encephalitis, vasculopathy, zoster paresis). MRI of the brain or spinal cord with and without contrast can show inflammation, edema, or ischemic changes.
  • Computed Tomography (CT):
    • Utility: May be used if MRI is contraindicated or unavailable, or for evaluating bone involvement in rare cases.
  • Chest X-ray/CT Chest:
    • Utility: If disseminated zoster with pulmonary involvement is suspected (e.g., cough, dyspnea, abnormal breath sounds), to evaluate for zoster pneumonitis.

Management

Acute Management

• Immediate:
  • Antiviral Therapy: Initiate as soon as possible, ideally within 72 hours of rash onset, to shorten the duration of acute pain and rash, promote healing, and reduce the risk/severity of post-herpetic neuralgia (PHN).
    • Valacyclovir: 1 gram orally three times daily (TID) for 7 days.
    • Famciclovir: 500 mg orally three times daily (TID) for 7 days.
    • Acyclovir: 800 mg orally five times daily (5x/day) for 7-10 days.
    • Note: Valacyclovir and famciclovir offer more convenient dosing schedules and better bioavailability than acyclovir. All are renally cleared; dose adjustment required for renal impairment (creatinine clearance <50 mL/min).
  • Pain Management: Initiate analgesia commensurate with pain severity.
    • First-line: Acetaminophen (e.g., 500-1000 mg every 4-6 hours, max 4g/day) or NSAIDs (e.g., Ibuprofen 400-600 mg every 6-8 hours, Naproxen 220-500 mg BID).
    • Neuropathic Pain: Consider adding medications for neuropathic pain early if pain is severe, especially in older adults with higher PHN risk. Gabapentinoids (gabapentin, pregabalin) or tricyclic antidepressants (TCAs) are common choices.
  • Wound Care: Keep lesions clean and dry. Cool compresses can soothe discomfort. Loose, non-adherent dressings may protect lesions.
• Stabilization:
  • Consultations:
    • Ophthalmology: Urgent consultation for any suspected zoster ophthalmicus.
    • ENT: Urgent consultation for suspected Ramsay Hunt syndrome.
    • Infectious Disease: For immunocompromised patients, disseminated zoster, or severe/atypical presentations.
  • Immunocompromised Patients: May require higher doses or intravenous antiviral therapy (e.g., Acyclovir IV 10 mg/kg every 8 hours for 7-10 days, or longer if severe/disseminated) and hospital admission.
• Emergency:
  • Disseminated Zoster with Visceral Involvement: Patients with widespread rash or evidence of internal organ involvement (e.g., pneumonitis, hepatitis, encephalitis) require immediate hospitalization and intravenous acyclovir.
  • Severe Neurological Complications: Patients presenting with motor weakness, myelitis, or encephalitis require urgent neurological evaluation and hospitalization for IV antiviral therapy.

Chronic Management

• Pharmacological (for Post-Herpetic Neuralgia - PHN): Pain persisting for ≥90 days after rash onset.
  • First-line:
    • Gabapentinoids: Gabapentin (starting 300 mg at bedtime, titrate up to 1800-3600 mg/day in 3 divided doses) or Pregabalin (starting 75 mg BID, titrate up to 300-600 mg/day in 2 divided doses).
    • Tricyclic Antidepressants (TCAs): Nortriptyline or desipramine (starting 10-25 mg at bedtime, titrate up to 75-150 mg/day). Amitriptyline (25-100 mg at bedtime) is also effective but has more anticholinergic side effects.
    • Topical Agents:
      • Lidocaine 5% patch: Apply to painful area for up to 12 hours/day. Effective for localized PHN.
      • Capsaicin 0.075% cream: Apply 3-4 times daily. Requires consistent use, can cause initial burning sensation. High-concentration (8%) capsaicin patch (Qutenza) can be administered in a clinic setting.
  • Second-line/Add-on:
    • Opioids: Tramadol or long-acting opioids may be considered for severe, refractory PHN, but with caution due to risks of addiction and side effects.
    • Duloxetine or Venlafaxine: Serotonin-norepinephrine reuptake inhibitors (SNRIs) can be effective for neuropathic pain.
    • Botulinum Toxin A: Emerging evidence for refractory PHN.
  • Interventional Pain Management: Nerve blocks (e.g., paravertebral, epidural, stellate ganglion blocks), spinal cord stimulation, or intrathecal drug delivery may be considered for severe, refractory cases.
• Non-pharmacological:
  • Education and Reassurance: Inform patients about the nature of PHN and realistic expectations for pain relief.
  • Psychological Support: Cognitive behavioral therapy (CBT), relaxation techniques, mindfulness.
  • Physical Therapy/Occupational Therapy: For functional limitations or allodynia.
  • Acupuncture: Some evidence suggests benefit for chronic pain conditions.
• Monitoring:
  • Acute Shingles: Monitor rash evolution, pain control, and for signs of complications.
  • PHN: Regular follow-up to assess pain severity, functional impairment, side effects of medications, and medication adherence. Adjust treatment as needed.

Treatment Algorithms

• First-Line (Acute Shingles):
  1. Diagnosis: Clinical presentation of unilateral dermatomal pain followed by a vesicular rash.
  2. Antiviral Therapy:
     • Start within 72 hours of rash onset: Valacyclovir 1g TID, Famciclovir 500mg TID, or Acyclovir 800mg 5x/day, all for 7 days.
     • If >72 hours but new lesions still appearing, or in immunocompromised patients: Still initiate antivirals.
  3. Pain Management:
     • Mild-Moderate Pain: Acetaminophen or NSAIDs.
     • Moderate-Severe Pain: Add neuropathic agents (gabapentinoids, TCAs) early, consider short-term opioids for severe acute pain.
  4. Wound Care: Keep lesions clean and dry, non-adherent dressings.
• Second-Line (Acute Shingles/Complications):
  1. Ophthalmic Zoster: Prompt ophthalmology consultation + systemic antivirals (Valacyclovir 1g TID for 7-10 days, or IV Acyclovir if severe). May require topical antivirals/steroids under ophthalmologist guidance.
  2. Ramsay Hunt Syndrome: Prompt ENT consultation + systemic antivirals (Valacyclovir 1g TID for 7-10 days, often with corticosteroids like Prednisone 60 mg/day for 5 days then taper).
  3. Disseminated Zoster/Immunocompromised Host: Hospitalization + IV Acyclovir (10 mg/kg IV every 8 hours for 7-14 days, or until no new lesions for 48 hours and internal organ improvement).
• Refractory Cases (PHN):
  1. Optimize First-Line PHN Agents: Titrate gabapentinoids or TCAs to maximum tolerated doses.
  2. Combination Therapy: Combine oral agents with topical agents (e.g., gabapentin + lidocaine patch).
  3. Switch/Add Agents: Try different classes (e.g., SNRI if TCAs ineffective).
  4. Referral to Pain Specialist: For interventional procedures (e.g., nerve blocks, spinal cord stimulator) or multimodal pain management programs.

Complications

• Common:
  • Post-Herpetic Neuralgia (PHN): The most common and debilitating complication, defined as pain persisting ≥90 days after rash onset. Risk increases with age, greater acute pain severity, larger rash area, and ophthalmic involvement.
  • Bacterial Superinfection: Of the skin lesions (e.g., Staphylococcus aureus, Streptococcus pyogenes), leading to cellulitis, impetigo, or rarely fasciitis.
  • Scarring and Pigmentation Changes: Permanent scars (pitted, hypertrophic) and post-inflammatory hyperpigmentation or hypopigmentation are common, especially if lesions were severe or infected.
• Serious:
  • Zoster Ophthalmicus (HZO) Complications: Can lead to keratitis, uveitis, scleritis, acute retinal necrosis, glaucoma, cataracts, and permanent vision loss if not promptly treated.
  • Ramsay Hunt Syndrome Complications: Permanent facial paralysis, hearing loss, or vestibular dysfunction.
  • Disseminated Zoster: Can involve vital organs leading to pneumonitis, hepatitis, encephalitis, myelitis, or disseminated intravascular coagulation (DIC). High mortality if untreated.
  • Neurological Complications:
    • Meningoencephalitis: Viral inflammation of brain and meninges.
    • Myelitis: Inflammation of the spinal cord, leading to motor weakness or sensory loss.
    • Vasculopathy: VZV can cause granulomatous arteritis, leading to stroke or transient ischemic attacks, particularly in the brain.
    • Motor Neuropathy (Zoster Paresis): Weakness or paralysis in muscles supplied by affected motor nerves, usually mononeuropathy or plexopathy.
• Long-term:
  • Chronic Pain: PHN can significantly impair quality of life, leading to sleep disturbances, depression, anxiety, and functional limitations.
  • Persistent Visual Impairment/Blindness: From HZO.
  • Permanent Facial Palsy/Hearing Loss: From Ramsay Hunt Syndrome.
  • Neuropathic Itch: Persistent itching in the affected dermatome, even after the pain resolves.

Prognosis

• Factors Affecting Outcome:
  • Age: Older age (especially >50-60 years) is the strongest predictor of increased severity, prolonged pain, and development of PHN.
  • Immunocompromise: Patients with weakened immune systems experience more severe, prolonged, and disseminated disease, higher complication rates, and increased mortality.
  • Severity of Acute Pain and Rash: Greater acute pain intensity and a larger area of rash predict a higher risk of PHN.
  • Location of Rash: Ophthalmic zoster carries a higher risk of ocular complications and PHN.
  • Early Antiviral Treatment: Initiation of antiviral therapy within 72 hours of rash onset significantly reduces acute pain, rash duration, and risk/severity of PHN.
• Survival:
  • Uncomplicated Shingles: Excellent prognosis, rarely fatal.
  • Disseminated Zoster: Mortality rate can be significant (e.g., 5-15%) if internal organs are involved, particularly in immunocompromised individuals.
  • CNS Complications: Meningoencephalitis carries a mortality risk and can lead to long-term neurological deficits.
• Quality of Life:
  • Acute Shingles: Can be severely debilitating due to pain and discomfort, interfering with daily activities and sleep.
  • PHN: Has a profound negative impact on quality of life, leading to chronic pain, sleep disturbances, depression, anxiety, social isolation, and reduced functional capacity. Patients with PHN often require long-term medication and may need multidisciplinary pain management.

Prevention

• Primary (Preventing initial occurrence of shingles):
  • Vaccination: The most effective method.
    • Recombinant Zoster Vaccine (RZV, Shingrix):
      • Recommendation: Recommended by ACIP for all immunocompetent adults aged ≥50 years, regardless of previous zoster episode or prior Zostavax vaccination. Also recommended for immunocompromised adults aged ≥18 years.
      • Dosing: 2 doses (0.5 mL each) administered intramuscularly, 2 to 6 months apart.
      • Efficacy: Highly effective, >90% efficacy against HZ and PHN in clinical trials, sustained for at least 7-10 years.
      • Side Effects: Common side effects include pain, redness, and swelling at the injection site, myalgia, fatigue, headache, shivering, fever, and gastrointestinal symptoms. These are usually mild to moderate and resolve within 2-3 days.
    • Zoster Vaccine Live (ZVL, Zostavax): No longer available for use in the U.S. as of November 18, 2020.
• Secondary (Early detection and intervention):
  • Prompt Diagnosis and Antiviral Treatment: Early initiation of antiviral therapy (within 72 hours of rash onset) in acute shingles can shorten the duration of acute pain and rash, and reduce the risk/severity of PHN. This is particularly important for those at higher risk of complications (e.g., elderly, immunocompromised).
• Tertiary (Preventing complications and managing existing ones):
  • Aggressive Pain Management: In the acute phase, adequate pain control may reduce the risk of PHN.
  • Multidisciplinary Pain Management for PHN: For established PHN, a combination of pharmacological, non-pharmacological, and interventional approaches aims to alleviate pain and improve quality of life.

Special Populations

• Pediatric:
  • Incidence: Shingles is rare in children but can occur. It is more common in children who had chickenpox in infancy (especially <1 year old) or who are immunocompromised (e.g., HIV, cancer, transplant).
  • Presentation: Usually milder than in adults, and PHN is very rare.
  • Management: Antiviral therapy (acyclovir 20 mg/kg orally QID for 5 days, max 800 mg/dose) is recommended for immunocompromised children and those with severe or complicated disease.
  • Prevention: Varicella vaccine (chickenpox vaccine) prevents primary VZV infection, thereby reducing the risk of future shingles. RZV is not currently recommended for routine use in children.
• Geriatric:
  • Increased Incidence and Severity: Highest incidence and severity of acute pain.
  • Increased PHN Risk: Significantly higher risk and severity of PHN. PHN is the most significant burden of shingles in this population.
  • Management: Prompt initiation of antiviral therapy is critical. Aggressive pain management, including early use of neuropathic agents, is important.
  • Prevention: Strongest recommendation for RZV vaccination due to high risk of HZ and PHN.
• Pregnancy:
  • Rare: Shingles in pregnancy is uncommon, as most women of childbearing age have immunity to VZV.
  • Fetal Risk: Unlike primary varicella (chickenpox) infection during pregnancy, which can cause congenital varicella syndrome, shingles (VZV reactivation) in pregnant women is generally not associated with increased risk of congenital anomalies. The virus does not typically disseminate hematogenously to the fetus during reactivation.
  • Management: Antiviral therapy (acyclovir, valacyclovir) is considered safe (FDA Pregnancy Category B) and can be used to treat acute shingles in pregnant women, especially if the rash is extensive, severe, or near the eye.
  • Vaccination: RZV is a recombinant vaccine and not live, but its safety in pregnancy has not been established, so it is generally deferred until after pregnancy.
• Comorbidities (Immunocompromised):
  • Increased Risk and Severity: Individuals with weakened immune systems (e.g., HIV/AIDS, cancer, organ transplant, chronic corticosteroid use) have a significantly higher risk of shingles, more severe and prolonged courses, and higher rates of dissemination and complications.
  • Management:
    • Antivirals: Often require higher doses or intravenous acyclovir (10 mg/kg IV every 8 hours) for longer durations (7-14 days or longer) to control the infection and prevent dissemination. Hospitalization is often necessary.
    • Prophylaxis: Antiviral prophylaxis (e.g., acyclovir, valacyclovir) may be used in highly immunocompromised patients (e.g., hematopoietic stem cell transplant recipients, solid organ transplant recipients) to prevent VZV reactivation.
    • Vaccination: RZV is recommended for immunocompromised adults aged ≥18 years depending on the specific condition and degree of immunosuppression, as per ACIP guidelines. Consultation with an infectious disease specialist may be warranted.

Clinical Pearls

• Diagnostic:
  • "Pain before rash": Is a classic prodromal symptom of shingles. Ask specifically about burning, itching, or hyperesthesia in the area that later developed the rash.
  • Unilateral, dermatomal distribution: This is the hallmark of shingles. If the rash crosses the midline or is widely scattered, consider disseminated zoster (especially in immunocompromised) or other diagnoses.
  • Hutchinson's Sign (Vesicles on nose tip): Always prompts an urgent ophthalmology referral for suspected zoster ophthalmicus, as it indicates involvement of the nasociliary nerve, increasing the risk of ocular complications.
  • Clinical diagnosis is usually sufficient: Lab tests are generally reserved for atypical presentations, immunocompromised patients, or when differentiation from HSV is necessary.
• Treatment:
  • Time is of the essence: Antiviral therapy should be initiated within 72 hours of rash onset to maximize benefits, especially in reducing the risk of PHN. However, even after 72 hours, consider antivirals if new lesions are still appearing or if the patient is immunocompromised.
  • Aggressive pain management: Do not underestimate acute zoster pain. Early and adequate pain control can improve patient comfort and potentially reduce the risk of PHN. Neuropathic agents (gabapentinoids, TCAs) can be initiated early, especially in older adults.
  • Vaccinate, vaccinate, vaccinate!: The recombinant zoster vaccine (Shingrix) is highly effective and safe. Recommend it to all eligible patients ≥50 years, and certain immunocompromised patients ≥18 years.
• Pitfalls:
  • Misdiagnosis: Confusing shingles with herpes simplex, contact dermatitis, or insect bites. The dermatomal distribution is key.
  • Delayed Antiviral Therapy: Missing the optimal window for antiviral treatment can lead to prolonged pain and increased risk of PHN.
  • Under-treating Pain: Can lead to significant patient distress, functional impairment, and potentially contribute to PHN development.
  • Missing Ocular or Neurological Complications: Failing to recognize red flag signs (Hutchinson's sign, facial weakness, severe headache, motor deficits) can lead to devastating and permanent complications. Always consider these possibilities, especially with head/face involvement.
  • Assuming Immunocompetence: Always ask about immunosuppressing conditions or medications, as this significantly impacts management and prognosis.

Recent Updates

• Guidelines:
  • ACIP Recommendations for RZV (Shingrix): The Advisory Committee on Immunization Practices (ACIP) updated its recommendations to strongly endorse RZV for all immunocompetent adults aged ≥50 years (since 2017) and expanded recommendations to include immunocompromised adults aged ≥18 years (since 2021). This replaced the live attenuated zoster vaccine (ZVL).
  • IDSA Guidelines (2014): Though somewhat older, the Infectious Diseases Society of America (IDSA) guidelines for the treatment of VZV infections remain a valuable reference, particularly for immunocompromised hosts.
• Evidence:
  • Long-term Efficacy of RZV: Studies continue to demonstrate high and durable efficacy of RZV (over 90%) against HZ and PHN for at least 7-10 years post-vaccination, with ongoing studies to determine even longer duration of protection.
  • Effectiveness in Immunocompromised Populations: Real-world data and clinical trials (e.g., ZOE-HERP-006, ZOE-HERP-007) have confirmed the significant benefit and safety of RZV in various immunocompromised patient groups (e.g., solid organ transplant recipients, hematopoietic stem cell transplant recipients, HIV-infected individuals, patients with hematologic malignancies).
• Controversies:
  • Role of Corticosteroids in Acute Shingles: While corticosteroids are often used with antivirals for Ramsay Hunt syndrome, their routine use in uncomplicated acute shingles to reduce acute pain or PHN risk is not widely supported by evidence and carries potential risks. Most guidelines do not recommend their routine use.
  • Optimal Duration of Antiviral Therapy for PHN Prevention: While 7 days is standard, research continues to explore if longer courses or higher doses could further reduce PHN risk, especially in high-risk patients, but current evidence does not support routine changes to standard durations.
  • Management of Zoster Sine Herpete: Diagnosis remains challenging due to the absence of a rash, requiring high clinical suspicion and reliance on laboratory testing (e.g., CSF PCR for VZV DNA), often after neurological symptoms develop.

Key References

• Guidelines:
  • Centers for Disease Control and Prevention (CDC) - ACIP Recommendations: For vaccination against herpes zoster. Available at www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/shingles.html
  • Infectious Diseases Society of America (IDSA) Guidelines: For the management of varicella-zoster virus infections. Clin Infect Dis. 2014 Mar;58(3):e51-78.
• Studies:
  • ZOE-50 and ZOE-70 Trials (for RZV efficacy): N Engl J Med. 2015;372(22):2087-96 (ZOE-50) and N Engl J Med. 2016;375(17):1609-18 (ZOE-70). These landmark trials established the high efficacy of RZV.
  • Studies on PHN Management: Various studies on specific agents for neuropathic pain (gabapentinoids, TCAs, lidocaine patches) published in neurology and pain management journals.
• Reviews:
  • UpToDate: Comprehensive topic reviews on "Epidemiology, clinical manifestations, and diagnosis of herpes zoster", "Treatment of herpes zoster in the immunocompetent host", "Postherpetic neuralgia", and "Prevention of herpes zoster". (Access via subscription).
  • Harrison's Principles of Internal Medicine: Chapter on "Varicella-Zoster Virus Infections."
  • Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases: Chapter on "Varicella-Zoster Virus."